JPMorgan Chase & Co. Purchases 187,364 Shares of Prothena Co. plc (NASDAQ:PRTA)

JPMorgan Chase & Co. increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA) by 93.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 387,350 shares of the biotechnology company’s stock after purchasing an additional 187,364 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.72% of Prothena worth $5,365,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PRTA. Barclays PLC grew its position in Prothena by 110.2% during the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock worth $1,592,000 after buying an additional 49,916 shares in the last quarter. SG Americas Securities LLC lifted its position in Prothena by 167.0% in the 4th quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 23,525 shares in the last quarter. Duncan Williams Asset Management LLC increased its stake in Prothena by 41.9% in the 4th quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company’s stock valued at $958,000 after buying an additional 20,450 shares during the last quarter. Rhumbline Advisers boosted its stake in Prothena by 1.8% in the fourth quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company’s stock valued at $930,000 after acquiring an additional 1,175 shares during the last quarter. Finally, Focused Wealth Management Inc purchased a new stake in Prothena in the 4th quarter worth about $445,000. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Prothena Trading Down 0.6 %

Shares of Prothena stock opened at $9.20 on Friday. The stock’s fifty day moving average price is $12.89 and its 200-day moving average price is $14.44. The firm has a market cap of $495.21 million, a P/E ratio of -4.00 and a beta of 0.07. Prothena Co. plc has a 12 month low of $9.10 and a 12 month high of $25.42.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The firm had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. Analysts forecast that Prothena Co. plc will post -4.04 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on PRTA. Chardan Capital reissued a “buy” rating and set a $40.00 price objective on shares of Prothena in a report on Friday, February 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a report on Friday, February 21st. Royal Bank of Canada lowered their price target on Prothena from $24.00 to $20.00 and set a “sector perform” rating on the stock in a report on Friday, February 21st. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Finally, Oppenheimer increased their price target on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.